Moderna stock extends decline after leaked data on melanoma vaccine trial
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna (MRNA) stock slid nearly 2% on Friday, extending its decline for a second day, after leaked data over the biotech company's results from a late-stage trial of its personalized melanoma vaccine. The stock fell as much as 26% on Thursday before closing down more than 17%…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishLeaked late-stage trial data wiped over $17 billion of market value from Moderna, which is now trading lower.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna shares fell as much as 26% on Thursday before closing down more than 17%.
- 02The leaked data concerns the personalized melanoma vaccine developed with Merck.
- 03Full data is scheduled for release on Saturday at the cancer conference in Madrid.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Moderna, Inc.201.55 USD+3.52%today -0.53%Negative Merck & Co., Inc.144.30 USD+0.16%today -2.00%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets